- Home
- MYMD
as 07-08-2024 4:00pm EST
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BALTIMORE |
| Market Cap: | 4.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 27.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.75 - $63.90 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MyMD Pharmaceuticals Inc. News
MYMD Breaking Stock News: Dive into MYMD Ticker-Specific Updates for Smart Investing
Business Wire
21 days ago
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
Business Wire
2 months ago
MyMD Pharmaceuticals Secures Strategic Investments
Business Wire
4 months ago
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Business Wire
5 months ago
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Simply Wall St.
5 months ago
Here's Why We're Not Too Worried About MediWound's (NASDAQ:MDWD) Cash Burn Situation
ACCESSWIRE
5 months ago
Envirotech Vehicles Announces EPA Clean School Bus Grant Program Award of $8.57 Million for 25 of its Fully Electric School Buses
Business Wire
6 months ago
Grove Collaborative Surpasses 15 Million Pounds of Nature-Bound Single-Use Plastic Collected Through Plastic Neutrality Commitment & Partnerships
GlobeNewswire
6 months ago
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Share on Social Networks:
Disclaimer
The information presented on this page, "MYMD MyMD Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.